Anidulafungina para tratamento de pacientes com candidemia e outras formas de candidíase invasiva
Comissão Nacional de Incorporação de Tecnologias no SUS.
Brasília; CONITEC; jun. 2022.
Não convencional Português | BRISA, BRISA | ID: biblio-1382014
Documentos relacionados
Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients.
Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults.
Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia.
Optimizing anidulafungin exposure across a wide adult body size range.
Antiviral activity and mechanism of the antifungal drug, anidulafungin, suggesting its potential to promote treatment of viral diseases.
Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations.
A New Marker of Echinocandin Activity in an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of Aspergillus fumigatus Infection.
Identification and susceptibility testing of oral candidiasis in advanced cancer patients.
Population Pharmacokinetics of Anidulafungin in Critically Ill Patients.
Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil.